Currencies / ALLO
ALLO: Allogene Therapeutics Inc
1.13
USD
0.05
(4.24%)
ALLO exchange rate has changed by -4.24% for today. During the day, the instrument was traded at a low of 1.11 and at a high of 1.20.
Follow Allogene Therapeutics Inc dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
ALLO News
- Fate Therapeutics: Recent Update Met With Selling, But Positives Exist
- Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO)
- Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
- Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
- Allogene Q2 Cash Tops $300 Million
- Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts
- Allogene stock continues ALPHA3 trial with standard FC regimen after safety event
- Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment
- This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics (NASDAQ:ALLO), AvalonBay Communities (NYSE:AVB)
- Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Allogene Therapeutics (NASDAQ:ALLO)
- Adicet Bio stock rating initiated at Buy by H.C. Wainwright
- Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
- Allogene Therapeutics at Jefferies Conference: Delays and Optimism
- Citi maintains buy rating on Allogene stock following ASCO data
- H.C. Wainwright maintains buy rating on Allogene stock after ASCO update
- Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
- Citizens JMP highlights key ASCO presentations
- Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
- Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner
- Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
- Allogene shares update on CAR T-cell therapies at ASCO meeting
- Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays
- Abrdn Life Sciences Investors Q4 2024 Commentary (NYSE:HQL)
Daily Range
1.11
1.20
Year Range
0.86
3.78
- Previous Close
- 1.18
- Open
- 1.18
- Bid
- 1.13
- Ask
- 1.43
- Low
- 1.11
- High
- 1.20
- Volume
- 1.878 K
- Daily Change
- -4.24%
- Month Change
- -5.83%
- 6 Months Change
- -39.25%
- Year Change
- -56.37%
30 August, Saturday